Mohammed Almoflihi
Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital
Papers
4
Total Citations
10
H-Index
2
About
Mohammed Almoflihi is a pioneering urologic surgeon and researcher whose work centers on advancing the surgical and prognostic management of bladder cancer through robotic-assisted techniques and liquid biopsy innovations. His most impactful contributions focus on robot-assisted radical cystectomy (RARC) for non-muscle-invasive bladder cancer (NMIBC), where his 12-year multicenter analysis (2025, 6 citations) provides critical long-term survival data, particularly for patients upstaged to muscle-invasive or node-positive disease. Almoflihi has also been at the forefront of integrating circulating tumor DNA (ctDNA) into post-cystectomy surveillance; his diagnostic accuracy study (2025, 2 citations) suggests that patients with undetectable ctDNA may safely undergo less intensive imaging, potentially reducing healthcare burden and patient anxiety. Further demonstrating his breadth, he has documented the feasibility of single-port radical nephroureterectomy combined with cystoprostatectomy (2024, 1 citation), showcasing technical innovation in complex multi-organ resections. With a cumulative impact of over 10 citations across his early-career publications, Almoflihi is shaping the future of personalized, minimally invasive urologic oncology—offering evidence that could redefine surveillance protocols and surgical standards for bladder cancer patients worldwide.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4